Title Page:

Title:

Influence of Poor Sleep on Cardiovascular Disease-Free Life Expectancy: A Multi-Resource-

Based Population Cohort Study

Author names and affiliations:

Bo-Huei Huang, M.Sc.

Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Borja del Pozo Cruz, Ph.D.

Centre for Active and Healthy Ageing, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark

Armando Teixeira-Pinto, Ph.D.

Affiliation: Sydney School of Public Health, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Peter A. Cistulli, Ph.D.

Charles Perkins Centre, Sydney Medical School, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Emmanuel Stamatakis, Ph.D.

Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, the University of Sydney, Camperdown, Australia.

Corresponding authors information:

Emmanuel Stamatakis, Ph.D.

Hub D17, Charles Perkins Centre L6 West, the University of Sydney, NSW 2006

+61-4-3270-4690

emmanuel.stamatakis@sydney.edu.au

3

1

Abstract

2 Background

The complexity of sleep hinders the formulation of sleep guidelines. Recent studies suggest that
different unhealthy sleep characteristics jointly increase the risks for cardiovascular disease
(CVD). This study aimed to estimate the differences in CVD-free life expectancy between
people with different sleep profiles.

7

8 Methods

9 We included 308683 middle-aged adults from the UK Biobank among whom 140181 had 10 primary care data linkage. We used an established composite sleep score comprising self-11 reported chronotype, duration, insomnia complaints, snoring, and daytime sleepiness to derive 12 three sleep categories: poor, intermediate, and healthy. We also identified three clinical sleep 13 disorders captured by primary care and inpatient records within two years before enrollment in the cohort: insomnia, sleep-related breathing disorders, and other sleep disorders. We estimated 14 15 sex-specific CVD-free life expectancy with three-state Markov models conditioning on survival at age 40 across different sleep profiles and clinical disorders. 16

17

18 Results

We observed a gradual loss in CVD-free life expectancy toward poor sleep such as, compared
with healthy sleepers, poor sleepers lost 1.80 [95% CI 0.96-2.75] and 2.31 [1.46-3.29] CVDfree years in females and males, respectively, while intermediate sleepers lost 0.48 [0.41-0.55]

4

- and 0.55 [0.49-0.61] years. Among men, those with clinical insomnia or sleep-related breathing
- disorders lost CVD-free life by 3.84 [0.61-8.59] or 6.73 [5.31-8.48] years, respectively. Among
- women, sleep-related breathing disorders or other sleep disorders were associated with 7.32
- 25 [5·33-10·34] or 1·43 [0·20-3·29] years lost, respectively.
- 26
- 27 Conclusions
- 28 Both self-reported and doctor-diagnosed poor sleep are negatively associated with CVD-free life,
- 29 especially pronounced in participants with sleep-related breathing disorders.

31

Main Text

32 Background

33 The World Health Organization has recognized sleep as a critical health state and health-related

behavior.(1) Although one-fourth of Europeans have insomnia,(2) with very few exceptions,(3)

there is very little national guidance on sleep, reflecting the complexity of sleep health as a

36 multi-dimensional behavior(4) as well as the lack of longitudinal evidence base on population-

37 wide effects of poor sleep.(3,5)

38

One major difficulty in evaluating the health impacts of sleep is its complexity as a biological 39 process and behavior.(4) Current estimates of optimal nocturnal sleep range in adults is seven to 40 less than nine hours per night. (6,7) with little evidence-based guidance on other health-related 41 sleep characteristics, such as quality and timing.(5,8) While most cohorts fail to capture the 42 multi-dimensional nature of sleep, recent studies have highlighted joint effects of different sleep 43 characteristics with risks for cardiovascular disease (CVD).(8,9) With a composite sleep score 44 comprising chronotype, duration, insomnia complaint, snoring, and daytime sleepiness, Fan et al. 45 found that healthy sleepers had a 35% lower risk of incident CVD than poor sleepers.(9) Using 46 the same set of sleep measures, our previous work further suggested that poor sleepers had a 47 39% higher risk of CVD mortality than healthy sleepers.(8) These findings indicated that a 48 traditional mutually adjusted approach could not capture the multiplicative effects of different 49 sleep characteristics, and the derived individual/independent effect of a single characteristic 50 could be spurious. 51

52	Compared to ratio-based estimation, years of life lost free of diseases, the difference in disease-								
53	free life expectancy between people with different characteristics provides a tangible metric on								
54	the burdens of exposures taking both morbidity and mortality into account. Life expectancy is								
55	easy to communicate to policymakers, media, and the general population.(10-12) However, no								
56	study has used such measures to evaluate the health burden of comprehensive sleep								
57	characteristics. Primary care (general practice) records have distinct advantages in capturing								
58	incident sleep disorders more comprehensively and objectively.(5)								
59									
60	To our knowledge, no prior sleep research has used primary care diagnoses to estimate the health								
61	burden of the compromised life expectancy of sleep disorders. Therefore, this study aimed to								
62	estimate CVD-free years of life lost among people with poor sleep, evaluated by self-report and								
63	clinical primary care diagnosis.								
64									
64 65	Methods								
64 65 66	Methods Data Source								
64 65 66 67	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that								
64 65 66 67 68	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that recruited participants in 22 assessment centers throughout England, Wales, and Scotland								
64 65 66 67 68 69	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that recruited participants in 22 assessment centers throughout England, Wales, and Scotland between 2006 and 2010 (https://www.ukbiobank.ac.uk/). Full cohort details can be found								
 64 65 66 67 68 69 70 	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that recruited participants in 22 assessment centers throughout England, Wales, and Scotland between 2006 and 2010 (https://www.ukbiobank.ac.uk/). Full cohort details can be found elsewhere.(13,14) In brief, more than half a million participants (response rate 6%) aged 40 to 69								
 64 65 66 67 68 69 70 71 	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that recruited participants in 22 assessment centers throughout England, Wales, and Scotland between 2006 and 2010 (https://www.ukbiobank.ac.uk/). Full cohort details can be found elsewhere.(13,14) In brief, more than half a million participants (response rate 6%) aged 40 to 69 provided informed consent to enrolment and data linkage to electronic health records. The								
 64 65 66 67 68 69 70 71 72 	Methods Data Source We retrieved individual data from the UK Biobank, a population-based prospective cohort that recruited participants in 22 assessment centers throughout England, Wales, and Scotland between 2006 and 2010 (https://www.ukbiobank.ac.uk/). Full cohort details can be found elsewhere.(13,14) In brief, more than half a million participants (response rate 6%) aged 40 to 69 provided informed consent to enrolment and data linkage to electronic health records. The baseline assessment included self-reported questionnaires, a computer-assisted personal								

7

74	records of dropping out participants, so retrieving loss of follow-up is inapplicable. By the time
75	we conducted the current study (October 2021), there were 502,459 participants with data
76	available. The National Health Service and the National Research Ethics Service have approved
77	the UK Biobank (Ref. 11/NW/0382).
78	
79	Electronic Health Records

The UK Biobank repository accesses national registered data on hospital inpatient diagnoses and death for all participants across the UK through the National Health Service (NHS). The NHS encoded records with the International Classification of Diseases (ICD), of which both the Ninth Revision (ICD-9) and the Tenth Revision (ICD-10) were available for the inpatient records, while only ICD-10 was applied to the death registry. Inpatient records were availed from 1981 onwards. Both registries were censored up to March 2021, with slight differences between

86 countries (**appendix pp 2**).

87

Primary care data on clinical events and prescriptions covered 227834 participants. Primary care clinical events were coded with Read codes version 2 (Read v2) or Clinical Terms Version 3 (CTV3), while prescriptions were mainly coded with Read v2, British National Formulary (BNF), or Dictionary of Medicines and Devices (dm+d). Further details of primary care data sources, cleaning, and harmonization are provided in **appendix pp 2, 19**. The primary care was censored to September 2018, with data availability varied between participants and was determined by the registration date with a primary care practice.

8

96 CVD Incidence and All-Cause Mortality

We identified the incidence of hospital inpatient disease events based on ICD-9 and ICD-10:
CVD (I01 to I09, I11, I13, I21 to I25, I27, I3, I4, I50, I51, I6, I7, I80 to I84, I87 to I9,
R54).(10,15) The corresponding ICD-9 was provided in appendix pp 3. The date of events and
death were retrieved from the NHS electronic health records described above.

101

102 Sleep Exposure

103 As part of the baseline questionnaire, participants reported five sleep characteristics, based on

104 which we further identified five healthy phenotypes, including no usual insomnia complaints,

adequate sleep duration (7 to <9 hr/d), no snoring, morning chronotype, and no frequent daytime

sleepiness.(9) We scored participants from 0 to 5, according to the count of healthy

107 characteristics and categorized them into three groups: "healthy sleep" (\geq 4 composite sleep

score); "intermediate sleep" (2 or 3 score); and "poor sleep" (≤ 1 score). This categorization has

109 been proven to distinguish different CVD risk profiles, and the simple addition approach showed

a similar predictive power to a weighted score.(9) The original questions and options were

111 provided in **appendix pp 3**. These definitions and scores have shown excellent convergent

112 validity with CVD incidence and mortality.(8,9)

113

114 We identified recent clinical sleep disorder events (two years before enrolment) based on

inpatient admissions, primary care clinical events, and sleep disorder-specific prescriptions (BNF

116 Chapter 4 Section 1: hypnotics and anxiolytics). Modified from the definition provided by the

117 American Sleep Association and American Academy of Sleep Medicine,(16,17) we

9

118	distinguished five different sleep disorders, including insomnia, hypersomnia, sleep-related
119	breathing disorders, circadian rhythm sleep disorders, and parasomnias (including sleep-related
120	bruxism). In addition, we grouped hypersomnia, circadian rhythm sleep disorders, parasomnias,
121	non-specific sleep disorders (e.g., "poor sleep pattern"), and sleep medication prescriptions
122	without a corresponding clinical event into "other sleep disorders." We provided detailed codes
123	for each classification system in appendix pp4-7 . Since the clinical diagnosis of sleep disorders
124	mainly refers to more than one self-reported sleep characteristic, we did not further integrate
125	both self-reported and clinically unhealthy sleep.

126

127 Statistical analysis

128 We set the follow-up from the UK Biobank enrollment to the date of death, inpatient or death registry censoring, or the 81st birthday, whichever came first. To avoid overestimation, we 129 constrained the censoring age (τ restriction) at 81, corresponding to the oldest age of death in the 130 analyzed sample.(18) Considering the pathophysiological differences in CVD risks between 131 sexes,(19) we stratified all our models by sex. To evaluate the sex-specific CVD-free residual 132 lifetime of participants with different exposures, we applied continuous-time three-state Cox 133 Markov survival models.(20,21) All participants started with the CVD-free state and 134 subsequently either (a) maintained healthy until censored, (b) were diagnosed with the disease(s) 135 136 and lived until censored, (c) maintained healthy then deceased, or (d) were diagnosed with the disease(s) then deceased. We estimated state-specific residual lifetime at age 40,(22) and 137 calculated the total and CVD-free years of life lost by comparing the marginal life expectancies 138 139 spent in a healthy state between the population with questionnaire-based poor/intermediate sleep (exposure) and those with healthy sleep (reference), or between the population with each 140

10

141	diagnosed sleep disorder (exposure) and those without (reference). Based on a priori defined
142	directed acyclic graphs (appendix pp 20),(23) we selected the following potential covariates:
143	age, socioeconomic status, mental health issues, perceived health, body mass index (BMI),
144	economic activity, and shift work, cigarette smoking, alcohol consumption, diet quality,
145	discretionary screen time, and physical activity. The detailed definitions and the original
146	questions of covariates were provided in appendix pp 8. Models examining each self-reported
147	sleep characteristic or diagnosed sleep disorder were further mutually adjusted for the remaining
148	characteristics or disorders. For all the life expectancy estimations, we applied median/ mean
149	value for categorical/numerous covariates, and for estimations of each self-reported sleep
150	characteristic/clinical sleep disorder, the remaining characteristics or disorders were set to
151	healthy.
152	
153	We obtained the 95% CIs for life expectancy estimations via nonparametric bootstrapping with
154	1000 iterations. All data were processed in SAS 9.4 (on secured local computers), and analyses
155	were performed on R 4.1.1 (on secured local computers) or R 4.0.4 (on the University of
156	Sydney's high performance computing cluster Artemis). To improve comparability, we repeated

all analyses with Fine-Gray sub-distribution hazards models, in which non-CVD death was

158 entered as a competing risk to incident CVD.(24) Covariates stayed the same as in the primary

analyses.

160

161 **Results**

11

162	We sequentially excluded participants with missing data in any of the five self-reported sleep
163	characteristics (n = 91802), with an inpatient or self-reported history of CVD (n = 54703), with
164	missing covariates ($n = 32765$), and with incident CVD or fatal events within the first two years
165	of follow-up ($n = 14506$), leaving 308683 participants for the core analysis of self-reported and
166	140181 participants for the clinically confirmed sleep events data (Figure 1, appendix pp 9-11).
167	Among the 308683 participants, with a mean follow-up of $11.8 (1.3)$ years from a mean age
168	56.2 (8.1), there were 13790 deaths from any cause and 53064 incident CVD, corresponding to
169	3653450 person-years at risk of death (Table 1). At baseline, 60% of the participants reported
170	healthy sleep, followed by 38% and 2% reporting intermediate and poor sleep, respectively
171	(Table 1, appendix pp 12-13). Participants who suffered from mental health problems,
172	perceived poor health, consumed a low-quality diet, had high BMI, faced higher socioeconomic
173	deprivation, retired, smoked/drank more, spent more discretionary time on screen, and exercised
174	less tended to have poor sleep in both sexes. Women were more likely to report healthy sleep
175	despite no appreciable differences in corresponding diagnoses (appendix pp 14-15).
176	
177	At age 40, total life expectancy was an additional 39.07 [38.95-39.17] and 38.29 [38.16-38.41]
178	years (appendix pp 16), while CVD-free life expectancy was 33.05 [32.91-33.21] and 30.03
179	[29.88-30.20] years for females and males (Table 2). Although total life expectancy did not
180	differ between sleep groups (Figure 2A, appendix pp 17), there was a gradual decrease in
181	CVD-free life expectancy toward a higher number of self-reported sleep characteristics in both

sexes (**Table 2, Figure 2A**). Women with poor sleep had a CVD-free life expectancy of 31.46

183 $[30\cdot36-32\cdot48]$ years, while those with healthy sleep had $33\cdot26$ $[33\cdot08-33\cdot46]$ years (difference:

184 1.80 [0.96-2.75]). The Women's intermediate group lost 0.48 [0.41-0.55] life years (**Table 2**,

12

185	Figure 3). A similar pattern emerged among males, yet more pronounced than among women.
186	Poorly sleeping men expected a 27.96 [26.80-29.02] CVD-free life years, and healthy sleepers
187	had 30.27 [30.07-30.49] years (difference: 2.31 [1.46-3.29]). The composite sleep categories
188	suggested joint effects of different sleep characteristics compared to models only focusing on a
189	single characteristic (Table 2, appendix pp 21). The corresponding hazard ratios (HR) for CVD
190	were 1.13 [1.05-1.22] and 1.17 [1.09-1.26] in poor sleepers compared to healthy ones among
191	females and males (appendix pp 22-25).
192	
193	Among the 140181 participants with primary care data available, 1203 had an insomnia
194	diagnosis in the last two years before their enrollment, while 2441 and 6489 were diagnosed with
195	sleep-related breathing disorders and other sleep disorders (appendix pp14-15). A confusion
196	matrix confirmed an assured negative predictive value of self-reported with diagnoses (appendix
197	pp 18). During an average follow-up of 11.8 (1.2) years and 1655597 person-years at risk of
198	death, 5996 died, and 23480 developed CVD. Total life expectancy was an additional 39.22

199 [39.05-39.37] and 38.29 [38.09-38.47] years (Figure 2B, appendix pp 16), while CVD-free life

expectancies were $33 \cdot 37 [33 \cdot 16 - 33 \cdot 60]$ and $30 \cdot 24 [30 \cdot 01 - 30 \cdot 50]$ years for females and males

201 (Table 2, Figure 2B). Contrary to self-report sleep, participants with any clinical sleep disorders

lost up to 1.16 [0.43-2.21] life compared to those without (**appendix pp 16**). Those diagnosed

with sleep disorders showed similar characteristics to those with poor self-reported sleep

204 (appendix pp14-15). Women diagnosed with sleep-related breathing disorders or other sleep

disorders lost 7.32 [5.33-10.34] (HR: 2.09 [1.87-2.35]) or 1.43 [0.2-3.29] (HR: 1.20 [1.08-

1.34]) CVD-free years of life compared to those without the corresponding diagnosis,

respectively (Table 2, Figure 3, appendix pp 26-29). In men, those with insomnia or sleep-

related breathing disorders expected a significant CVD-free life loss by 3.84 [0.61-8.59] (HR:

208

209	1·49 [1·23-1·80]) or 6·73 [5·31-8·48] (HR: 1·83 [1·68-1·99]) years, respectively. Complete
210	estimations of life expectancy and HRs were provided in the appendix pp 16, 22-29.
211	
212	Discussion
213	To our knowledge, the current study provides the first comprehensive analyses of sleep measures
214	with life expectancy, utilizing cohort study data and primary care electronic health records to
215	identify sleep disorders. At 40 years of age, participants with self-reported poor sleep lost 1.8
216	and 2.3 years of life free of CVD in women and men, respectively, compared to those who
217	reported healthy sleep. The diagnosis of sleep-related breathing disorders was associated with the
218	largest loss of life years without diseases in both sexes, up to 7.3 years, while diagnosed
219	insomnia compromised life years in men by 3.8 years. Our findings strongly suggest that people
220	with either self-reported or diagnosed unhealthy sleep have less life expectancy free of CVD.
221	
222	"Seven to 9 hours of good-quality sleep on a regular basis, with consistent bed and wake-up
223	times" is the only national (Canada) guideline on sleep,(3) based on a review of reviews on
224	duration and a de novo systematic review of the regularity/consistency and
225	chronotype/timing.(5,6) Although we could not address sleep regularity/consistency as it was
226	outside the scope of the UK Biobank questionnaires, aligned with this guideline, our finding
227	supported that sleep duration and chronotype impact CVD-free life expectancy in both sexes.
228	However, "sleep quality" is a poorly defined term encompassing various measures and
229	characteristics, so in the present study, we applied available CVD risk factors, including

14

insomnia complaints, snoring, and daytime sleepiness. Despite the controversial outcomes 230 between recent systematic reviews of insomnia, (25,26) our analyses showed that insomnia 231 impacted CVD-free life expectancy differently between sexes, as highlighted by the distinct 232 effects of self-reported complaints and clinical insomnia. Although we found no association of 233 self-reported/co-sleeper-reported snoring with life expectancy outcomes, clinical sleep-related 234 235 breathing disorders were found to compromise CVD-free life expectancy in both sexes by up to 7.3 years. Our results are consistent with those from the only existing review on topic 26 and 236 suggest that women with frequent daytime sleepiness impacted the number of CVD-free years. 237 238 The absence of clinical diagnosis of excessive daytime sleepiness and the low prevalence (*i.e.*, 33 out of 140181 participants) of circadian rhythm sleep disorders, the corresponding clinical 239 240 diagnosis of chronotype, prohibited us from further investigating objective measurements. 241 Besides the independent effect of each characteristic, composite sleep measures provide more 242 comprehensive insights and a more coherent public health message(3) and are increasingly used 243

exposures, the present results, consistent with existing individual studies,(8,9) suggested that

in cohort studies.(8,9) Although there is still no systematic review available on composite sleep

246 people with multiple poor sleep characteristics had a shorter CVD-free year in both sexes. Our

study further suggested that this association is more prominent in males, while the very few

longitudinal results of sleep and health examining sex as an effect modifier are

244

incongruous.(6,27–29) The systematic review conducted by He et al. (2020) found that the

250 mortality risk of long sleep duration was higher in females, but the mortality risk of short sleep

251 was higher in males.(27) However, the systematic review of the Canadian national guideline and

252 recent prospective studies found no sex differences in the mortality and CVD risks of non-

15

adequate sleep duration.(6,28,29) Since capacities of sleep measurements vary between cohorts,
arbitrariness in the included sleep measures and the subsequent adjustments hamper the
aggregation of findings. More studies with detailed outcomes on each sleep measure are
warranted to facilitate future harmonization and consensus on essential sleep characteristics
selections.

258

This study's main strength and novelty is the use of primary care data linkage to identify sleep 259 260 disorders, allowing us to compare the differences between clinical sleep disorders and selfreported poor sleep with detailed sleep questionnaires. The large sample size further allows us to 261 explore effect size with adequate statistical power. National hospitalization and death records 262 263 across all participants reduce the potential measurement bias of outcomes and allow us to perform life expectancy analyses comprising morbidity and mortality. However, our study has 264 several limitations. First, sleep-related clinical events other than insomnia and sleep-related 265 breathing disorders were rare and thereby had to be grouped, compromising the specificity of our 266 analyses. Second, the UK Biobank has poor representativeness by oversampling the high 267 socioeconomic status, while our exclusion criteria further oversampled the healthy population 268 (Appendix pp 9-11), so our findings might not be generalizable to a population with different 269 socioeconomic status. The low prevalence of clinical sleep disorders also indicated a potential 270 underestimation due to the undiagnosed. However, recent UK Biobank evidence suggests that 271 poor representativeness is unlikely to influence the associations between lifestyle exposures and 272 mortality.(30) Third, we could not rule out immortal-time bias as the current analyses only 273 274 followed up mid-age healthy adults. Fourth, we could not distinguish CVD recovery and relapse events based on available data, so we could not avoid overestimating the time spent on diseases. 275

16

276	Fifth, we only considered baseline measurements of exposures and covariates to maintain
277	statistical power, although our previous finding suggested a reasonable temporal consistency.(8)
278	Lastly, in the current study, we conservatively chose underlying conditions as covariables since
279	comorbidities could be on the causal pathway (i.e., mediators). We could not eliminate the
280	potential residual confounding (Appendix pp 20), so the true causality could be biased.
281	
282	Conclusions
283	In summary, this study provides further support for the advantage of a composite sleep score
284	based on easily applied self-reported questions. With access to primary care records, our findings
285	shed light on how clinical sleep disorders could be adversely associated with CVD-free life
286	expectancy. These results could lay the cornerstone for future research on early prevention
287	against poor sleep and improving CVD-free life expectancy among poor sleepers. Especially, we
288	hope that the current outcomes can serve as a reference for policymakers and professionals to
289	develop national sleep guidelines.

291	List of Abbreviations
292	BMI, Body Mass Index
293	BNF, British National Formulary
294	CTV3, Clinical Terms Version 3
295	CVD, Cardiovascular Disease
296	dm+d, Dictionary of Medicines and Devices
297	HR, Hazard Ratios
298	ICD, International Classification of Diseases
299	NHS, National Health Service
300	Read v2, Read codes version 2
301	

18

302

Declarations

303 Ethics approval

- 304 This study was a secondary analysis of previously collected data so additional ethical approval
- 305 was not required. The National Health Service and the National Research Ethics Service have
- approved the UK Biobank (Ref. 11/NW/0382) while all participants gave written informed

307 consent.

308 Consent for publication

309 Not applicable.

310 Availability of data and materials

- 311 The data that support the findings of this study are available from the UK Biobank but
- restrictions apply to the availability of these data, which were used under license for the current
- study, and so are not publicly available. Data are however available from the authors upon
- reasonable request and with permission of the UK Biobank.

315 Competing interests

316 All authors declare no competing interests.

317 Funding

- BH is a PhD student supported by the Taiwanese Ministry of Education and the University of
- 319 Sydney. ES is funded by the Australian National Health and Medical Research Council through
- an Investigator Grant Level 2 (APP1180812). No conflict of interest was declared as the funding
- sources had no involvement in the study design; in the collection, analysis, and interpretation of
- 322 data; in the writing of the report; or in the decision to submit the article for publication.

19

323 Authors' contributions

- BH: conceptualization, software, formal analysis, visualization, writing original draft. BPC &
- AT: methodology, software, validation, writing review & editing. PC: conceptualization,
- 326 methodology, writing review & editing. ES: funding acquisition, project administration,
- 327 resources, supervision, writing review & editing.

328 Acknowledgements

- 329 This research has been conducted using the UK Biobank Resource under Application Number
- 25813. The authors gratefully thank all the participants and professionals contributing to the UK
- Biobank. In addition, the authors acknowledge the Sydney Informatics Hub and the Artemis
- 332 University of Sydney's high-performance computing cluster Artemis for providing the
- computing resources and support to complete the research reported in this paper.

20

References

- 1. World Health Organization. Guidelines on physical activity, sedentary behaviour and sleep for children under 5 years of age [Internet]. World Health Organization; 2019 [cited 2021 Sep 23]. 33 p. Available from: https://apps.who.int/iris/handle/10665/311664
- Baglioni C, Altena E, Bjorvatn B, Blom K, Bothelius K, Devoto A, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. J Sleep Res [Internet]. 2020 Apr [cited 2021 Sep 23];29(2). Available from: https://onlinelibrary.wiley.com/doi/10.1111/jsr.12967
- 3. Ross R, Chaput JP, Giangregorio LM, Janssen I, Saunders TJ, Kho ME, et al. Canadian 24-Hour Movement Guidelines for Adults aged 18–64 years and Adults aged 65 years or older: an integration of physical activity, sedentary behaviour, and sleep. Appl Physiol Nutr Metab [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S57–102. Available from: https://cdnsciencepub.com/doi/10.1139/apnm-2020-0467
- 4. Buysse DJ. Sleep Health: Can We Define It? Does It Matter? Sleep [Internet]. 2014 Jan 1 [cited 2022 Oct 9];37(1):9–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902880/
- Chaput JP, Dutil C, Featherstone R, Ross R, Giangregorio L, Saunders TJ, et al. Sleep timing, sleep consistency, and health in adults: a systematic review. Appl Physiol Nutr Metab [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S232–47. Available from: https://cdnsciencepub.com/doi/10.1139/apnm-2020-0032
- Chaput JP, Dutil C, Featherstone R, Ross R, Giangregorio L, Saunders TJ, et al. Sleep duration and health in adults: an overview of systematic reviews. Appl Physiol Nutr Metab [Internet]. 2020 Oct [cited 2021 Jul 12];45(10 (Suppl. 2)):S218–31. Available from: https://cdnsciencepub.com/doi/10.1139/apnm-2020-0034
- Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep Health J Natl Sleep Found [Internet]. 2015 Mar 1 [cited 2020 Jan 31];1(1):40–3. Available from: https://www.sleephealthjournal.org/article/S2352-7218(15)00015-7/abstract
- Huang BH, Duncan MJ, Cistulli PA, Nassar N, Hamer M, Stamatakis E. Sleep and physical activity in relation to all-cause, cardiovascular disease and cancer mortality risk. Br J Sports Med [Internet]. 2022;56:718–24. Available from: 10.1136/bjsports-2021-104046
- Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. Eur Heart J [Internet]. 2020 Mar 14 [cited 2020 Nov 11];41(11):1182–9. Available from: http://academic.oup.com/eurheartj/article/41/11/1182/5678714
- Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. The Lancet [Internet]. 2019 Nov 16 [cited 2021 Jun 10];394(10211):1827–35. Available from: https://www.sciencedirect.com/science/article/pii/S0140673619323165
- 11. Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ [Internet]. 2020 Jan 8

21

[cited 2021 Jun 10];368:16669. Available from: https://www-bmjcom.ezproxy.library.sydney.edu.au/content/368/bmj.16669

- del Pozo Cruz B, Biddle SJH, Gardiner PA, Ding D. Light-Intensity Physical Activity and Life Expectancy: National Health and Nutrition Survey. Am J Prev Med [Internet]. 2021 Sep 1 [cited 2021 Aug 18];61(3):428–33. Available from: https://www.sciencedirect.com/science/article/pii/S0749379721001768
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med [Internet]. 2015 Mar 31 [cited 2020 Apr 28];12(3):e1001779. Available from: https://dx.plos.org/10.1371/journal.pmed.1001779
- Conroy M, Sellors J, Effingham M, Littlejohns TJ, Boultwood C, Gillions L, et al. The advantages of UK Biobank's open-access strategy for health research. J Intern Med [Internet]. 2019 Oct 1 [cited 2021 Jul 10];286(4):389–97. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.12955
- Zhao M, Veeranki SP, Magnussen CG, Xi B. Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. BMJ [Internet]. 2020 Jul 1 [cited 2020 Jul 4];370. Available from: http://www.bmj.com/content/370/bmj.m2031
- 16. Authors ASA, Reviewers RP at ASA, physicians W certified sleep MD, scientists, editors, ASA writers for. Sleep Disorders ICD 10 Codes - Research & Treatments | American Sleep Assoc [Internet]. American Sleep Association. 2021 [cited 2021 Jun 11]. Available from: https://www.sleepassociation.org/healthprofessionals/sleep-disorders-icd-10-codes-names/
- Sateia MJ. International Classification of Sleep Disorders-Third Edition. Chest [Internet]. 2014 Nov 1 [cited 2021 Sep 1];146(5):1387–94. Available from: https://www.sciencedirect.com/science/article/pii/S0012369215524070
- Plana-Ripoll O, Canudas-Romo V, Weye N, Laursen TM, McGrath JJ, Andersen PK. lillies: An R package for the estimation of excess Life Years Lost among patients with a given disease or condition. PLOS ONE [Internet]. 2020 Mar 6 [cited 2021 Jun 10];15(3):e0228073. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228073
- DeFilippis EM, Van SHGC. Is it Time for Sex-Specific Guidelines for Cardiovascular Disease? J Am Coll Cardiol [Internet]. 2021 Jul 13 [cited 2021 Jul 9];78(2):189–92. Available from: https://www.jacc.org/doi/abs/10.1016/j.jacc.2021.05.012
- 20. van den Hout A. ELECT: Estimation of life expectancies using continuous-time multi-state survival models. ELECT Version 02 Vignette Ed2016. 2014;
- 21. Jackson C. Multi-State Models for Panel Data: The msm Package for R. J Stat Softw [Internet]. 2011 Jan 4 [cited 2021 Sep 21];38(1):1–28. Available from: https://www.jstatsoft.org/index.php/jss/article/view/v038i08
- Nyberg ST, Batty GD, Pentti J, Virtanen M, Alfredsson L, Fransson EI, et al. Obesity and loss of diseasefree years owing to major non-communicable diseases: a multicohort study. Lancet Public Health [Internet]. 2018 Oct 1 [cited 2021 Jul 10];3(10):e490–7. Available from: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30139-7/abstract

- 22
- Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GTH. Robust causal inference using directed acyclic graphs: the R package 'dagitty.' Int J Epidemiol [Internet]. 2017 Jan 15 [cited 2021 Sep 23];45(6):1887–94. Available from: https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyw341
- 24. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime Risks of Cardiovascular Disease. N Engl J Med [Internet]. 2012 Jan 26 [cited 2021 Nov 6];366(4):321–9. Available from: https://doi.org/10.1056/NEJMoa1012848
- 25. Ge L, Guyatt G, Tian J, Pan B, Chang Y, Chen Y, et al. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep Med Rev [Internet]. 2019 Dec 1 [cited 2020 Mar 11];48:101215. Available from: http://www.sciencedirect.com/science/article/pii/S1087079219301753
- 26. Lovato N, Lack L. Insomnia and mortality: A meta-analysis. Sleep Med Rev [Internet]. 2019 Feb 1 [cited 2020 Mar 11];43:71–83. Available from: http://www.sciencedirect.com/science/article/pii/S1087079218300741
- 27. He M, Deng X, Zhu Y, Huan L, Niu W. The relationship between sleep duration and all-cause mortality in the older people: an updated and dose-response meta-analysis. BMC Public Health [Internet]. 2020 Dec [cited 2022 Jan 26];20(1):1179. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09275-3
- Cao Z, Xu C, Yang H, Li S, Wang Y. The Role of Healthy Lifestyle in Cancer Incidence and Temporal Transitions to Cardiometabolic Disease. JACC CardioOncology [Internet]. 2021 Dec [cited 2022 Aug 27];3(5):663–74. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2666087321002593
- Yang L, Xi B, Zhao M, Magnussen CG. Association of sleep duration with all-cause and disease-specific mortality in US adults. J Epidemiol Community Health [Internet]. 2021 Jun [cited 2022 Aug 27];75(6):556– 61. Available from: https://jech.bmj.com/lookup/doi/10.1136/jech-2020-215314
- 30. Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is Cohort Representativeness Passé? Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank. Epidemiology [Internet]. 2021 Mar [cited 2021 Apr 30];32(2):179–88. Available from: https://journals.lww.com/epidem/fulltext/2021/03000/is_cohort_representativeness_pass___poststratified.4. aspx

Figure Titles and Footnotes

Figure 1. The participants' exclusion flowchart

Abbreviations: CVD, cardiovascular diseases. The detailed missing pattern was provided in **appendix pp 16-18**.

Figure 2. Total and cardiovascular disease-free life expectancy at age 40 among participants with different (A)

questionnaire-based composite sleep scores or (B) diagnosed sleep disorders

The results were adjusted for age, socioeconomic status, mental health issues, perceived health, body mass

index (BMI), economic activity and shift work, cigarette smoking, alcohol consumption, diet quality,

discretionary screen time, and physical activity. Full estimations of each life expectancy were provided in

appendix pp 14.

Tables and Footnotes

	Females				Males				A 11
Variables	Poor	Intermediate	Healthy	Total	Poor	Intermediate	Healthy	Total	All
n	3407 (2)	61966 (36)	108173 (62)	173546	3072 (2)	55408 (41)	76657 (57)	135137	308683
Early Chronotype	244 (7)	26097 (42)	83570 (77)	109911 (63)	272 (9)	21666 (39)	61522 (80)	83460 (62)	193371 (63)
Adequate Duration (7 to <9 hr/d)	107 (3)	25030 (40)	96644 (89)	121781 (70)	142 (5)	25696 (46)	68307 (89)	94145 (70)	215926 (70)
No Usual Insomnia Complaints	120 (4)	24898 (40)	96648 (89)	121666 (70)	179 (6)	34074 (61)	71636 (93)	105889 (78)	227555 (74)
No Snoring	219 (6)	32929 (53)	92525 (86)	125673 (72)	153 (5)	16488 (30)	53623 (70)	70264 (52)	195937 (63)
No Frequent Daytime Sleepiness	2534 (74)	59611 (96)	107709 (100)	169854 (98)	2119 (69)	53252 (96)	76375 (100)	131746 (97)	301600 (98)
Follow-up Time (yr)	11.8 (1.3)	11.8 (1.2)	11.9 (1.1)	11.9 (1.2)	11.7 (1.5)	11.8 (1.4)	11.8 (1.3)	11.8 (1.4)	11.8 (1.3)
Incident CVD	714 (21)	9973 (16)	14264 (13)	24951 (14)	854 (28)	12161 (22)	15098 (20)	28113 (21)	53064 (17)
All-Cause Death	180 (5)	2396 (4)	3476 (3)	6052 (3)	213 (7)	3380 (6)	4145 (5)	7738 (6)	13790 (4)
Age of Enrollment	56.6 (7.4)	56.6 (7.7)	55.8 (8.2)	56.1 (8.0)	55.7 (8.0)	56.1 (8.2)	56.3 (8.2)	56.2 (8.2)	56.2 (8.1)
Socioeconomic Status									
Highest Deprivation	1062 (31)	14579 (24)	22137 (20)	37778 (22)	925 (30)	13109 (24)	15874 (21)	29908 (22)	67686 (22)
2nd Deprivation	853 (25)	15910 (26)	27294 (25)	44057 (25)	795 (26)	13619 (25)	18868 (25)	33282 (25)	77339 (25)
3rd Deprivation	780 (23)	15732 (25)	28919 (27)	45431 (26)	684 (22)	14159 (26)	20287 (26)	35130 (26)	80561 (26)
Least Deprivation	712 (21)	15745 (25)	29823 (28)	46280 (27)	668 (22)	14521 (26)	21628 (28)	36817 (27)	83097 (27)
Mental Health Issues	2000 (59)	28506 (46)	38360 (35)	68866 (40)	1286 (42)	15619 (28)	16710 (22)	33615 (25)	102481 (33)
Perceived Health									
Excellent	248 (7)	8917 (14)	25133 (23)	34298 (20)	235 (8)	7938 (14)	16906 (22)	25079 (19)	59377 (19)
Good	1556 (46)	36941 (60)	68436 (63)	106933 (62)	1337 (44)	32088 (58)	46949 (61)	80374 (59)	187307 (61)
Fair	1138 (33)	13631 (22)	13320 (12)	28089 (16)	1063 (35)	13132 (24)	11692 (15)	25887 (19)	53976 (17)
Poor	465 (14)	2477 (4)	1284 (1)	4226 (2)	437 (14)	2250 (4)	1110(1)	3797 (3)	8023 (3)
Body Mass Index (kg/m2)									
<30	1986 (58)	45184 (73)	89543 (83)	136713 (79)	1877 (61)	40272 (73)	61634 (80)	103783 (77)	240496 (78)
30 to <40	1190 (35)	14968 (24)	17226 (16)	33384 (19)	1084 (35)	14339 (26)	14474 (19)	29897 (22)	63281 (21)
>= 40	231 (7)	1814 (3)	1404 (1)	3449 (2)	111 (4)	797 (1)	549 (1)	1457 (1)	4906 (2)
Economic Activity and Shift Work									

Table 1. The basic characteristics of participants with different questionnaire-based sleep characteristic	ics
------------------------------------------------------------------------------------------------------------	-----

Retired/not in the workforce	1651 (48)	26566 (43)	42105 (39)	70322 (41)	1180 (38)	18159 (33)	24779 (32)	44118 (33)	114440 (37)
Employed not in shift work	1417 (42)	29820 (48)	57847 (53)	89084 (51)	1381 (45)	29616 (53)	43483 (57)	74480 (55)	163564 (53)
Employed in night shift work	166 (5)	2501 (4)	3307 (3)	5974 (3)	325 (11)	4577 (8)	4505 (6)	9407 (7)	15381 (5)
Employed in day shift work	173 (5)	3079 (5)	4914 (5)	8166 (5)	186 (6)	3056 (6)	3890 (5)	7132 (5)	15298 (5)
Cigarette Smoking									
Never	1671 (49)	34819 (56)	68510 (63)	105000 (61)	1266 (41)	26288 (47)	41967 (55)	69521 (51)	174521 (57)
Cessation	1189 (35)	20647 (33)	32600 (30)	54436 (31)	1278 (42)	21370 (39)	27170 (35)	49818 (37)	104254 (34)
Current	547 (16)	6500 (10)	7063 (7)	14110 (8)	528 (17)	7750 (14)	7520 (10)	15798 (12)	29908 (10)
Alcohol Drinking									
Never	170 (5)	2892 (5)	5170 (5)	8232 (5)	64 (2)	1114 (2)	1791 (2)	2969 (2)	11201 (4)
Quit	175 (5)	2059 (3)	3051 (3)	5285 (3)	137 (4)	1522 (3)	2177 (3)	3836 (3)	9121 (3)
< 14 UK Units/wk	2178 (64)	40306 (65)	74036 (68)	116520 (67)	1175 (38)	21933 (40)	33350 (44)	56458 (42)	172978 (56)
14 to <28 UK Units/wk	553 (16)	11667 (19)	19728 (18)	31948 (18)	687 (22)	14793 (27)	21668 (28)	37148 (27)	69096 (22)
>= 28 UK Units/wk	331 (10)	5042 (8)	6188 (6)	11561 (7)	1009 (33)	16046 (29)	17671 (23)	34726 (26)	46287 (15)
Dietary Quality									
Poor	226 (7)	2535 (4)	3034 (3)	5795 (3)	491 (16)	6921 (12)	6730 (9)	14142 (10)	19937 (6)
Intermediate	2082 (61)	36714 (59)	61282 (57)	100078 (58)	2041 (66)	36785 (66)	50107 (65)	88933 (66)	189011 (61)
Healthy	1099 (32)	22717 (37)	43857 (41)	67673 (39)	540 (18)	11702 (21)	19820 (26)	32062 (24)	99735 (32)
Discretionary Screen Time (hr/d)	4.5 (2.6)	3.8 (2.0)	3.4 (1.8)	3.6 (1.9)	4.7 (2.6)	4.2 (2.2)	3.8 (2.0)	4.0 (2.1)	3.8 (2.0)
Physical Activity									
No MVPA	850 (25)	11686 (19)	15716 (15)	28252 (16)	729 (24)	8942 (16)	9287 (12)	18958 (14)	47210 (15)
< 10 MET hrs/wk	470 (14)	7131 (12)	10440 (10)	18041 (10)	382 (12)	6531 (12)	7354 (10)	14267 (11)	32308 (10)
10 to <20 MET hrs/wk	469 (14)	9779 (16)	17268 (16)	27516 (16)	427 (14)	8314 (15)	11144 (15)	19885 (15)	47401 (15)
>= 20 MET hrs/wk	1618 (47)	33370 (54)	64749 (60)	99737 (57)	1534 (50)	31621 (57)	48872 (64)	82027 (61)	181764 (59)

Data were shown in N (% vertically) or Mean (SD) for categorical or continuous variables, respectively. Abbreviations: CVD, cardiovascular diseases; MET, metabolic equivalent task; MVPA, moderate-to-vigorous physical activity. A summary without sex stratification was provided in **appendix pp 9-10**, and a characteristic table of participants with different diagnosed sleep disorders was provided in **appendix pp 11-12**.

	Females		Males	
Exposures	CVD-Free Life Expectancy	CVD-Free Years of Life Lost	CVD-Free Life Expectancy	CVD-Free Years of Life Lost
Total included participants	33.05 [32.91-33.21]		30.03 [29.88-30.20]	
Primary Care Subsample	33.37 [33.16-33.60]		30.24 [30.01-30.50]	
Sleep Characteristic*				
Usual Insomnia Complaints	32.98 [32.67-33.28]	0.30 [0.18-0.43]	30.09 [29.66-30.50]	0.14 [-0.05-0.35]
No Usual Insomnia Complaints	33.28 [33.07-33.47]		30.23 [30.01-30.45]	
Inadequate Sleep Duration	32.63 [32.32-32.93]	0.63 [0.51-0.76]	29.86 [29.50-30.21]	0.32 [0.19-0.45]
Adequate Duration	33.26 [33.05-33.45]		30.18 [29.94-30.42]	
Snoring	33.07 [32.76-33.37]	-0.01 [-0.08-0.06]	30.06 [29.80-30.32]	0.09 [0.00-0.17]
No Snoring	33.26 [33.06-33.45]		30.41 [30.16-30.66]	
Evening Chronotype	33.21 [32.93-33.47]	0.19 [0.07-0.32]	30.20 [29.90-30.51]	0.35 [0.31-0.4]
Morning Chronotype	33.20 [32.99-33.39]		30.29 [30.05-30.52]	
Frequent Daytime Sleepiness	32.33 [31.00-33.37]	0.92 [0.04-2.06]	29.85 [28.40-30.98]	0.41 [-0.55-1.66]
Infrequent Daytime Sleepiness	33.24 [33.06-33.41]		30.26 [30.05-30.46]	
Composite Sleep Score ⁺				
≤ 1	31.46 [30.36-32.48]	1.90 [1.10-2.76]	27.96 [26.80-29.02]	2.21 [1.48-3.07]
2	32.73 [32.27-33.19]	0.62 [0.41-0.85]	29.36 [28.86-29.86]	0.82 [0.61-1.02]
3	32.78 [32.51-33.09]	0.57 [0.5-0.65]	29.84 [29.57-30.15]	0.33 [0.21-0.45]
4	33.32 [33.09-33.58]	0.04 [-0.03-0.11]	30.30 [30.06-30.57]	-0.13 [-0.25-0.01]
5	33.36 [33.07-33.68]		30.17 [29.81-30.56]	
Poor (≤ 1)	31.46 [30.36-32.48]	1.80 [0.96-2.75]	27.96 [26.80-29.02]	2.31 [1.46-3.29]
Intermediate (2 to 3)	32.77 [32.54-33.03]	0.48 [0.41-0.55]	29.72 [29.48-29.97]	0.55 [0.49-0.61]
Healthy (≥ 4)	33.26 [33.08-33.46]		30.27 [30.07-30.49]	
Clinical Diagnosed Sleep Disorder*				
Insomnia	31.77 [28.23-33.78]	1.58 [-0.24-4.97]	26.32 [21.34-29.73]	3.84 [0.61-8.59]
Without This Condition	33.36 [33.11-33.57]		30.16 [29.92-30.39]	
Sleep-Related Breathing Disorders	26.01 [22.80-28.21]	7.32 [5.33-10.34]	23.48 [21.54-25.10]	6.73 [5.31-8.48]
Without This Condition	33.34 [33.09-33.56]		30.21 [29.96-30.44]	
Other Sleep Disorders	31.91 [29.81-33.34]	1.43 [0.20-3.29]	29.19 [27.11-30.77]	0.99 [-0.36-2.85]
Without This Condition	33.33 [33.09-33.55]		30.18 [29.93-30.41]	
With Any Sleep Disorders	30.64 [29.46-31.74]	2.73 [1.85-3.72]	26.46 [25.30-27.58]	3.79 [2.89-4.71]
Without Any Sleep Disorders	33.37 [33.16-33.60]		30.24 [30.01-30.50]	

Table 2. Cardiovascular-free life expectancy and years of life lost at age 40 among participants with different sleep exposures

Data were shown in estimation [95% CI], with values in bold denoting statistical significance. For all the estimations, we applied median or mean value for categorical or numerous covariates, respectively, and for estimations of each self-reported sleep characteristic or each diagnosed sleep disorder, the remaining characteristics or disorders were set to healthy. *Compared to those without poor sleep characteristics/diagnosed conditions. †Compared to the healthiest group (five score/healthy group). Full estimations of each life expectancy were provided in **appendix pp 14**. Abbreviations: CVD, cardiovascular diseases.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

N = 502,459

in the present UK Biobank dataset





N = 308,683 included in the analyses based on the self-reported



Primary Care Records

N = 140,181 included in the analyses based on primary care and inpatient records



Questionnaire-Based Composite Sleep Scores



